Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, Guimarães CRW, Liu S, Niosi M, Skoura A, Tess D.

J Med Chem. 2018 Apr 12;61(7):3114-3125. doi: 10.1021/acs.jmedchem.8b00152. Epub 2018 Apr 3.

PMID:
29570292
2.

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, Ford K, Guimarães CR, Hepworth D, Jiao W, LaPerle J, Liu S, Londregan A, Loria PM, Mathiowetz AM, Munchhof M, Orr ST, Petersen DN, Price DA, Skoura A, Smith AC, Wang J.

ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33. doi: 10.1021/acsmedchemlett.5b00215. eCollection 2015 Nov 12.

3.

MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.

Schwaid AG, Su C, Loos P, Wu J, Nguyen C, Stone KL, Kanyo J, Geoghegan KF, Bhattacharya SK, Dow RL, Buckbinder L, Carpino PA.

ACS Chem Biol. 2015 Dec 18;10(12):2667-71. doi: 10.1021/acschembio.5b00679. Epub 2015 Sep 30.

PMID:
26422651
4.

Undesired versus designed enzymatic cleavage of linkers for liver targeting.

Chirapu SR, Bauman JN, Eng H, Goosen TC, Strelevitz TJ, Sinha SC, Dow RL, Finn MG.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1144-7. doi: 10.1016/j.bmcl.2013.12.126. Epub 2014 Jan 8.

5.

Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.

Griffith DA, Dow RL, Huard K, Edmonds DJ, Bagley SW, Polivkova J, Zeng D, Garcia-Irizarry CN, Southers JA, Esler W, Amor P, Loomis K, McPherson K, Bahnck KB, Préville C, Banks T, Moore DE, Mathiowetz AM, Menhaji-Klotz E, Smith AC, Doran SD, Beebe DA, Dunn MF.

J Med Chem. 2013 Sep 12;56(17):7110-9. doi: 10.1021/jm401033t. Epub 2013 Aug 27.

PMID:
23981033
6.

Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.

Dow RL, Andrews MP, Li JC, Michael Gibbs E, Guzman-Perez A, Laperle JL, Li Q, Mather D, Munchhof MJ, Niosi M, Patel L, Perreault C, Tapley S, Zavadoski WJ.

Bioorg Med Chem. 2013 Sep 1;21(17):5081-97. doi: 10.1016/j.bmc.2013.06.045. Epub 2013 Jul 1.

PMID:
23871442
7.

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.

Filipski KJ, Guzman-Perez A, Bian J, Perreault C, Aspnes GE, Didiuk MT, Dow RL, Hank RF, Jones CS, Maguire RJ, Tu M, Zeng D, Liu S, Knafels JD, Litchfield J, Atkinson K, Derksen DR, Bourbonais F, Gajiwala KS, Hickey M, Johnson TO, Humphries PS, Pfefferkorn JA.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4571-8. doi: 10.1016/j.bmcl.2013.06.036. Epub 2013 Jun 20.

PMID:
23831135
8.

Medicinal chemistry design principles for liver targeting through OATP transporters.

Tu M, Mathiowetz AM, Pfefferkorn JA, Cameron KO, Dow RL, Litchfield J, Di L, Feng B, Liras S.

Curr Top Med Chem. 2013;13(7):857-66. Review.

PMID:
23578029
9.

High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid.

Chirapu SR, Rotter CJ, Miller EL, Varma MV, Dow RL, Finn MG.

Curr Top Med Chem. 2013;13(7):837-42. Review.

PMID:
23578027
10.

Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors.

Huard K, Bagley SW, Menhaji-Klotz E, Préville C, Southers JA Jr, Smith AC, Edmonds DJ, Lucas JC, Dunn MF, Allanson NM, Blaney EL, Garcia-Irizarry CN, Kohrt JT, Griffith DA, Dow RL.

J Org Chem. 2012 Nov 16;77(22):10050-7. doi: 10.1021/jo3014808. Epub 2012 Nov 5.

PMID:
23127254
11.

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.

Dow RL, Carpino PA, Gautreau D, Hadcock JR, Iredale PA, Kelly-Sullivan D, Lizano JS, O'Connor RE, Schneider SR, Scott DO, Ward KM.

ACS Med Chem Lett. 2012 Mar 21;3(5):397-401. doi: 10.1021/ml3000325. eCollection 2012 May 10.

12.

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.

Dow RL, Andrews M, Aspnes GE, Balan G, Michael Gibbs E, Guzman-Perez A, Karki K, Laperle JL, Li JC, Litchfield J, Munchhof MJ, Perreault C, Patel L.

Bioorg Med Chem Lett. 2011 Oct 15;21(20):6122-5. doi: 10.1016/j.bmcl.2011.08.028. Epub 2011 Aug 12.

PMID:
21908190
13.

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Dow RL, Li JC, Pence MP, Gibbs EM, LaPerle JL, Litchfield J, Piotrowski DW, Munchhof MJ, Manion TB, Zavadoski WJ, Walker GS, McPherson RK, Tapley S, Sugarman E, Guzman-Perez A, DaSilva-Jardine P.

ACS Med Chem Lett. 2011 Mar 18;2(5):407-12. doi: 10.1021/ml200051p. eCollection 2011 May 12.

14.

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.

Hadcock JR, Carpino PA, Iredale PA, Dow RL, Gautreau D, Thiede L, Kelly-Sullivan D, Lizano JS, Liu X, Van Deusen J, Ward KM, O'Connor RE, Black SC, Griffith DA, Scott DO.

BMC Pharmacol. 2010 Aug 16;10:9. doi: 10.1186/1471-2210-10-9.

15.

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

Hadcock JR, Griffith DA, Iredale PA, Carpino PA, Dow RL, Black SC, O'Connor R, Gautreau D, Lizano JS, Ward K, Hargrove DM, Kelly-Sullivan D, Scott DO.

Biochem Biophys Res Commun. 2010 Apr 2;394(2):366-71. doi: 10.1016/j.bbrc.2010.03.015. Epub 2010 Mar 6.

PMID:
20211605
16.

Thyroid receptor agonists for the treatment of androgenetic alopecia.

Li JJ, Mitchell LH, Dow RL.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):306-8. doi: 10.1016/j.bmcl.2009.10.109. Epub 2009 Oct 29.

PMID:
19900809
17.

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.

Dow RL, Hadcock JR, Scott DO, Schneider SR, Paight ES, Iredale PA, Carpino PA, Griffith DA, Hammond M, Dasilva-Jardine P.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5351-4. doi: 10.1016/j.bmcl.2009.07.130. Epub 2009 Aug 6.

PMID:
19683918
18.

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, Schneider SR, Paight ES, Griffith DA, Scott DO, O'Connor RE, Nduaka CI.

J Med Chem. 2009 May 14;52(9):2652-5. doi: 10.1021/jm900255t.

PMID:
19351113
19.

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Griffith DA, Hadcock JR, Black SC, Iredale PA, Carpino PA, DaSilva-Jardine P, Day R, DiBrino J, Dow RL, Landis MS, O'Connor RE, Scott DO.

J Med Chem. 2009 Jan 22;52(2):234-7. doi: 10.1021/jm8012932.

PMID:
19102698
20.

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

Carpino PA, Griffith DA, Sakya S, Dow RL, Black SC, Hadcock JR, Iredale PA, Scott DO, Fichtner MW, Rose CR, Day R, Dibrino J, Butler M, Debartolo DB, Dutcher D, Gautreau D, Lizano JS, O'connor RE, Sands MA, Kelly-Sullivan D, Ward KM.

Bioorg Med Chem Lett. 2006 Feb;16(3):731-6. Epub 2005 Nov 2.

PMID:
16263283
21.

Beta3-adrenergic agonists: potential therapeutics for obesity.

Dow RL.

Expert Opin Investig Drugs. 1997 Dec;6(12):1811-25.

PMID:
15989582
22.

Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists.

Dow RL, Paight ES, Schneider SR, Hadcock JR, Hargrove DM, Martin KA, Maurer TS, Nardone NA, Tess DA, DaSilva-Jardine P.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3235-40.

PMID:
15149682
23.

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.

Dow RL, Schneider SR, Paight ES, Hank RF, Chiang P, Cornelius P, Lee E, Newsome WP, Swick AG, Spitzer J, Hargrove DM, Patterson TA, Pandit J, Chrunyk BA, LeMotte PK, Danley DE, Rosner MH, Ammirati MJ, Simons SP, Schulte GK, Tate BF, DaSilva-Jardine P.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):379-82.

PMID:
12565933
24.

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation.

Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA.

J Biol Chem. 1996 Jan 12;271(2):695-701.

25.

Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors.

Dow RL, Chou TT, Bechle BM, Goddard C, Larson ER.

J Med Chem. 1994 Jul 8;37(14):2224-31.

PMID:
7518523
26.

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents.

Dow RL, Bechle BM, Chou TT, Clark DA, Hulin B, Stevenson RW.

J Med Chem. 1991 May;34(5):1538-44.

PMID:
2033578
27.

Distribution, Hosts, and Morphological Characteristics of Tylenchulus palustris in Florida and Bermuda.

Dow RL, Inserra RN, Esser RP, Langdon KR.

J Nematol. 1990 Oct;22(4S):724-8.

28.

Differential isolatoion of Pythium species from soil by means of selective media,temperature, and pH.

Lunsden RD, Ayers WA, Dow RL.

Can J Microbiol. 1975 May;21(5):606-12.

PMID:
236086
29.
30.

Natural Redistributon of a Quahog Population.

Dow RL, Wallace DE.

Science. 1955 Oct 7;122(3171):641-2. No abstract available.

PMID:
17776466

Supplemental Content

Support Center